# US 2016/0250158 A1 · Methods and compositions for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250158 A1
- Document ID: US20160250158A1
- Status: Published application
- Kind: A1
- Application number: 13/382,263
- Filed: 2010-06-07
- Published: 2016-09-01
- Earliest claimed: 2009-06-05
- Inventors: Joan McInyre Caron
- Web page: https://patentgrep.com/patent/US20160250158A1

## CPC

- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant invention provides methods and compositions for the treatment and prevention of cell proliferative disorders.

## Claims

### Claim 1

A method for treating a cell proliferative disorder in a subject comprising administering to the subject a therapeutically effective amount of methyl sulfone, thereby treating the cell proliferative disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell proliferative disorder is cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cancer is a solid tumor cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the solid tumor cancer is selected from the group consisting of ovarian, brain, colon, lung, melanoma, bladder, breast or prostate cancer.

### Claim 5 (depends on 2)

The method of claim 2, wherein the cell proliferative disorder is a hematological cancer.

### Claim 6 (depends on 5)

The method of claim 5, wherein the hematological cancer is leukemia or lymphoma.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has previously received chemotherapeutic or radiation therapy which was unsuccessful.

### Claim 8 (depends on 1)

The method of claim 1, wherein the methyl sulfone is administered systemically.

### Claim 9 (depends on 1)

The method of claim 1, wherein the methyl sulfone is administered locally.

### Claim 10 (depends on 1)

The method of claim 1, wherein the methyl sulfone is targeted to the location of the cell proliferative disorder.

### Claim 11 (depends on 10)

The method of claim 10, wherein the methyl sulfone is formulated in a micro or nanoparticle.

### Claim 12 (depends on 1)

The method of claim 1, wherein an area having a solid tumor is sprayed with or bathed in methyl sulfone.

### Claim 13 (depends on 12)

The method of claim 12, wherein the solid tumor is removed prior to treatment with methyl sulfone.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 15 (depends on 14)

The method of claim 14, wherein the mammal is a human.

### Claim 16

A method of treating cancer in a subject in need thereof, comprising the step of: separately administering to the subject a composition comprising: methyl sulfone; and a chemotherapeutic agent.

### Claim 17 (depends on 16)

The method as claimed in claim 16, wherein the administration of methyl sulfone and the chemotherapeutic agent is simultaneous.

### Claim 18 (depends on 16)

The method as claimed in claim 16, wherein the administration of the composition methyl sulfone and the chemotherapeutic agent is sequential.

### Claim 19 (depends on 16)

The method as claimed in claim 16, wherein the chemotherapeutic agent is chosen from the group of: doxil, topotecan, DNA-altering drugs, carboplatin, antimetabolites, gemcitabine, drugs that prevent cell division, vincristine, anti-angiogenic agents, and pazopanib.

### Claim 20

A method of treating a subject having a solid tumor surgically removed comprising spraying or bathing the area containing the tumor with methyl sulfone after removal of the tumor and prior to the completion of the surgery.

### Claim 21

A method of treating ovarian cancer in a subject comprising: contacting the ovaries with methyl sulfone; thereby treating ovarian cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein the ovaries are sprayed with methyl sulfone.

### Claim 23

A method of preventing the spread of cancer in subject having a solid tumor surgically removed comprising: bathing or spraying the area containing the tumor with methyl sulfone after removal of the tumor and prior to the completion of the surgery; thereby preventing the spread of cancer in the subject.

### Claim 24

A method of inducing a cell to revert to a normal cellular phenotype from a cancer cell phenotype comprising:
contacting the cell with an effective amount of methyl sulfone;
thereby inducing a phenotypic change from a cancer cell phenotype to a normal cell phenotype.

### Claim 25

A pharmaceutical composition comprising methyl sulfone and a pharmaceutically-acceptable diluent or carrier.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25 wherein the composition is a gel or cream.

### Claim 27 (depends on 25)

The pharmaceutical composition of claim 25 wherein the composition is a solution.

### Claim 28 (depends on 25)

The pharmaceutical composition of claim 25, wherein the composition comprises a liposome or nanoparticle.

### Claim 29 (depends on 25)

The pharmaceutical composition of claim 25 wherein the composition comprises a delayed release dosage form.

### Claim 30 (depends on 25)

The pharmaceutical composition of claim 25 wherein the composition is formulated for aerosolization.

### Claim 31

A patch for the treatment of skin cancer comprising methyl sulfone.

### Claim 32 (depends on 31)

The patch of claim 31, further comprising a pharmaceutically-acceptable diluent or carrier.

### Claim 33

A kit for the treatment of a cell proliferative disorder comprising methyl sulfone and instructions for use.

### Claim 34 (depends on 33)

The kit of claim 33, further comprising an applicator.

### Claim 35 (depends on 34)

The kit of claim 34, wherein the applicator is a sponge, spray bottle, or aerosolizer.
